Pfiz­er gene ther­a­py ups lev­els of dy­s­trophin ex­pres­sion in Duchenne tri­al — but an­oth­er safe­ty set­back mars re­sults

Pfiz­er’s gene ther­a­py group is back up at bat with a fresh up­date of da­ta from its Phase Ib study for a gene ther­a­py in­tend­ed …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.